Alphabet Inc.
Long book
$4.02B
Q1 2026
Positions
26
Top-10 weight
94%
concentration
Last quarter
+17.7%
SPY +14.8%
Turnover
28%
of book per quarter
Strategy in plain words
auto-generated from filingsAlphabet Inc. is a concentrated fundamental stock-picker, running a $4.02B US long book across 26 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: CME GROUP INC, PLANET LABS PBC, AST SPACEMOBILE INC, REVOLUTION MEDICINES INC, ARM HOLDINGS PLC-ADR.
Over the last 9 quarters its long book ran on average 4.9pp per quarter ahead of the S&P 500, beating the index in 6 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-9.7%
Q2 2024
-3.9%
Q3 2024
+5.6%
Q4 2024
-12.9%
Q1 2025
+37.5%
Q2 2025
+16.2%
Q3 2025
+22.8%
Q4 2025
+10.9%
Q1 2026
+17.7%
Sector allocation
Technology 36%
Financials 29%
Communications 20%
Healthcare 14%
Long book by quarter
What does Alphabet Inc. own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| CME CME GROUP INC | Financials | 3.5M | $1.03B | 25.6% | New |
| PL PLANET LABS PBC | Technology | 35.2M | $985.2M | 24.5% | +10.4% |
| ASTS AST SPACEMOBILE INC | Communications | 8.9M | $741.1M | 18.5% | Held |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 3.3M | $320.2M | 8.0% | -1.6% |
| FRSH FRESHWORKS INC-CL A | Technology | 16.2M | $130.1M | 3.2% | Held |
| PATH UIPATH INC - CLASS A | Technology | 7.0M | $78.1M | 1.9% | Held |
| TEM TEMPUS AI INC-CL A | Technology | 1.6M | $70.1M | 1.7% | Held |
| GTLB GITLAB INC-CL A | Technology | 2.7M | $59.0M | 1.5% | Held |
| PRME PRIME MEDICINE INC | Healthcare | 16.6M | $57.6M | 1.4% | Held |
| LIFE ETHOS TECHNOLOGIES INC CL-A | Financials | 3.8M | $42.1M | 1.0% | New |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 1.4M | $41.4M | 1.0% | Held |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | Healthcare | 2.8M | $25.3M | 0.6% | Held |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 1.6M | $15.6M | 0.4% | -0.3% |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 684.3K | $11.3M | 0.3% | -8.1% |
| VERA VERA THERAPEUTICS INC | Healthcare | 241.3K | $9.7M | 0.2% | Held |
| SANA SANA BIOTECHNOLOGY INC | Healthcare | 2.8M | $8.1M | 0.2% | Held |
| BEAM BEAM THERAPEUTICS INC | Healthcare | 321.6K | $7.7M | 0.2% | Held |
| LYEL LYELL IMMUNOPHARMA INC | Healthcare | 293.3K | $5.9M | 0.1% | Held |
| OSCR OSCAR HEALTH INC - CLASS A | Financials | 482.0K | $5.5M | 0.1% | Held |
| FIG FIGMA INC-CL A | Technology | 215.6K | $4.6M | 0.1% | Held |
| SPRO SPERO THERAPEUTICS INC | Healthcare | 890.0K | $2.1M | 0.1% | Held |
| HYPR HYPERFINE INC | Healthcare | 898.7K | $971K | 0.0% | Held |
| TNYA TENAYA THERAPEUTICS INC | Healthcare | 915.7K | $632K | 0.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 8, 2026 | 27 | $4.02B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 32 | $2.58B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 7, 2025 | 40 | $2.41B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 1, 2025 | 39 | $2.14B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 2, 2025 | 44 | $1.58B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 7, 2025 | 44 | $1.72B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 8, 2024 | 46 | $1.84B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 2, 2024 | 46 | $1.97B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 3, 2024 | 47 | $2.51B | canonical | SEC ↗ |
Similar funds
Sanders Capital, LLCGATES FOUNDATION TRUSTEAGLE CAPITAL MANAGEMENT LLCWoodbridge Co LtdAlecta Tjanstepension OmsesidigtMubadala Investment Co PJSCH&H International Investment, LLCNewlands Management Operations LLCINVESTOR ABIndependent Franchise Partners LLPPineStone Asset Management Inc.Pentwater Capital Management LP